Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
Editas Medicine (Nasdaq: EDIT), a leading gene editing company, has scheduled a webinar for Tuesday, September 2, 2025, at 8:00 a.m. ET to announce their lead in vivo development candidate. The presentation will be accessible through a webcast link and the company's investor relations website.
The webinar will focus on revealing details about their latest advancement in gene editing technology aimed at developing transformative medicines for serious diseases. A replay will be available in the Investors section of the Editas Medicine website following the presentation.
Editas Medicine (Nasdaq: EDIT), azienda leader nell'editing genetico, terrà un webinar martedì 2 settembre 2025 alle 8:00 ET per presentare il suo candidato principale per lo sviluppo in vivo. La presentazione sarà fruibile tramite webcast e dalla sezione investor relations del sito aziendale.
Il webinar illustrerà i dettagli del più recente progresso nella tecnologia di editing genetico volto a sviluppare terapie innovative per malattie gravi. Successivamente, la registrazione sarà disponibile nella sezione Investor del sito di Editas Medicine.
Editas Medicine (Nasdaq: EDIT), compañía líder en edición genética, ha programado un seminario web para el martes 2 de septiembre de 2025 a las 8:00 a.m. ET para anunciar su candidato principal para desarrollo in vivo. La presentación podrá seguirse mediante webcast y en la web de relaciones con inversores de la compañía.
El webinar se centrará en revelar detalles sobre su último avance en tecnología de edición genética orientado a desarrollar medicamentos transformadores para enfermedades graves. Tras la presentación, habrá una retransmisión disponible en la sección de Inversores del sitio web de Editas Medicine.
Editas Medicine (나스닥: EDIT), 유전자 편집 분야의 선도 기업이 2025년 9월 2일 화요일 동부시간(ET) 오전 8시에 인비보 개발 선도 후보 물질을 발표하는 웨비나를 개최합니다. 발표는 웹캐스트 링크와 회사 투자자 관계 사이트를 통해 시청할 수 있습니다.
이번 웨비나는 중증 질환 치료제를 목표로 하는 최신 유전자 편집 기술 발전의 세부 내용을 공개하는 데 초점을 맞춥니다. 발표 후에는 Editas Medicine 웹사이트의 투자자(Investors) 섹션에서 다시보기 영상을 제공할 예정입니다.
Editas Medicine (Nasdaq: EDIT), entreprise de premier plan en édition génomique, organise un webinaire mardi 2 septembre 2025 à 8h00 ET pour annoncer son candidat principal en développement in vivo. La présentation sera accessible via un lien webcast et sur le site relations investisseurs de la société.
Le webinaire présentera les détails de leur dernière avancée en technologie d'édition génétique visant à développer des médicaments transformateurs contre des maladies graves. Un replay sera disponible dans la rubrique Investors du site d'Editas Medicine après la présentation.
Editas Medicine (Nasdaq: EDIT), ein führendes Unternehmen im Bereich Geneditierung, hat ein Webinar für Dienstag, den 2. September 2025, um 8:00 Uhr ET angesetzt, um seinen führenden In-vivo-Entwicklungskandidaten vorzustellen. Die Präsentation ist über einen Webcast-Link und die Investor-Relations-Seite des Unternehmens abrufbar.
Im Webinar werden Details zu dem neuesten Fortschritt in der Geneditierungstechnologie präsentiert, der auf die Entwicklung bahnbrechender Medikamente gegen schwere Erkrankungen abzielt. Eine Aufzeichnung wird anschließend im Bereich Investors auf der Editas-Medicine-Website verfügbar sein.
- None.
- None.
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will host a webinar on Tuesday, September 2, 2025, at 8:00 a.m. ET to announce the selection of its lead in vivo development candidate.
Webinar Presentation Details:
The live and archived webcast of the Company’s webinar presentation will be accessible through this webcast link, or through the Events & Presentations page of the “Investors” section of the Company’s website.
A replay of the webinar will be available upon conclusion of the webinar in the Investors section of the Editas Medicine website at https://www.editasmedicine.com/.
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Investor and Media Contacts: ir@editasmed.com media@editasmed.com
FAQ
When is Editas Medicine (EDIT) hosting its webinar to announce the lead in vivo development candidate?
How can investors access Editas Medicine's (EDIT) September 2025 webinar presentation?
Will there be a replay available of Editas Medicine's (EDIT) September 2025 development candidate announcement?
What will Editas Medicine (EDIT) announce during their September 2025 webinar?
